The next meeting of the PBAC will be in July 2026. At this meeting committee will be considering a request from Medison Pharma Australia Pty limited to list Vutrisiran for the treatment of adult patients with wild-type or hereditary ATTR-CM who have documented evidence of the transthyretin precursor protein present who have experienced at least one episode of hospitalisation that was a direct result of heart failure or have clinical evidence of heart failure without hospitalisation that required treatment with a diuretic for improvement.
View the Agenda for this meeting using the link below (scroll down to VUTRISIRAN on Page 14).
